In this article, we will list the Investors’ Stock Portfolio: Top 5 Penny Stocks To Buy. Please visit Investors’ Stock Portfolio: Top 10 Penny Stocks To Buy if you would like to see the extended list and the methodology behind it.
5. Cabaletta Bio Inc. (NASDAQ:CABA)
Share Price: $3.68
Stock Upside Potential: 321.20%
Year to Date Gain: 66.06%
Number of Hedge Fund Holders: 29
Cabaletta Bio Inc. (NASDAQ:CABA) is one of the top penny stocks to buy in investors’ stock portfolio. On May 14, Cabaletta Bio Inc. (NASDAQ:CABA) delivered positive clinical and translational data from the first four patients in the lowest dose cohort evaluating preconditioning-free (PC-free) rese-cel, an investigational, autologous CAR T cell therapy for the treatment of autoimmune diseases.
It also presented manufacturing and translational data from the first two autoimmune patients treated with rese-cel treated using Cellares Cell Shuttle platform. It became clear that a higher rese-cel dose would be required in the absence of preconditioning. In addition, 50% of the patients demonstrated compelling, drug-free responses for six months.
Consequently, PC-free rese-cel has the potential to enhance access for patients in CAR T centers. The company has already signed a long-term commercial supply agreement that will ensure rese-cel is produced for thousands of patients at the lowest cost of goods, with minimal capital investment.
Cabaletta is on track to announce initial data from the lowest-dose cohort of lupus patients dosed with preconditioning. The company also plans to advance rese-cel toward BLA submission as it eyes a commercial launch.
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T-cell therapies designed to reset the immune system and provide potentially curative treatments for patients with autoimmune diseases.
4. Denison Mines Corp. (NYSEAMERICAN:DNN)
Share Price $3.67
Stock Upside Potential: 30.73%
Year to Date Gain: 13.20%
Number of Hedge Fund Holders: 31
Denison Mines Corp. (NYSEAMERICAN:DNN) is one of the top penny stocks to buy in investors’ stock portfolio. On May 12, Denison Mines Corp. (NYSEAMERICAN:DNN) reiterated its impressive start to the year. Its Phoenix In-Situ Recovery uranium mine became the first large-scale Canadian uranium mining project to receive all regulatory approvals to commence construction.
The company has already made its final investment decision for the project. The management team has started executing schedule-critical site preparation and early works construction activities, with plans to achieve first uranium production in mid-2028.
Denison remains well positioned to grow its uranium sales books, backed by a combination of uranium holdings, active McLean Lake mine production, and large-scale mine production from the Phoenix and Gryphon deposits.
In the first quarter, the company entered into a near-term sale commitment for uranium deliveries within a year. The company is to sell 550,000 pounds of U3O8 between the second quarter of 2026 and the first quarter of 2027 at an average price of US$99.07 per pound.
Denison Mines Corp. (NYSEAMERICAN:DNN) is a Canadian uranium exploration and development company focused primarily on the Athabasca Basin region of northern Saskatchewan, Canada. Their core activities include mining project development, uranium exploration, and environmental services.
3. Allogene Therapeutics, Inc. (NASDAQ:ALLO)
Share Price: $2.05
Stock Upside Potential: 325.06%
Year to Date Gain: 59.26%
Number of Hedge Fund Holders: 32
Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the top penny stocks to buy in investors’ stock portfolio. On May 13, Allogene Therapeutics, Inc. (NASDAQ:ALLO) reiterated positive interim results in the ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel), its investigational, allogeneic CAR T-cell therapy targeting CD19.
In ongoing trials, Cema-cel was well tolerated, with no treatment-related serious adverse events. In addition, there were no cases of cytokine release syndrome, let alone immune effector cell-associated neurotoxicity syndrome. Additionally, the company is working on ALLO-329, a purpose-built Allogeneic CAR-T for autoimmune disease. The therapy incorporates the company’s proprietary Dagger technology.
Amid pipeline development, Allogene Therapeutics spent $32 million in research and development expenses in the first quarter, including $2.7 million of non-cash stock-based compensation expenses. The company exited the quarter with a net loss of $42.6 million, or $0.18 per share. It also had $266.9 million in cash and cash equivalents, which acts as a sufficient cash runway into the first quarter of 2029.
Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a clinical-stage biotechnology company pioneering “off-the-shelf” CAR T cell therapies (AlloCAR T) for the treatment of blood cancers, solid tumors, and autoimmune diseases.
2. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Share Price: $4.10
Stock Upside Potential: 115.45%
Year to Date Gain: 57.14%
Number of Hedge Fund Holders: 33
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the top penny stocks to buy in investors’ stock portfolio. On June 1, research firm Citizens reiterated a Market Outperform rating on Iovanace Biotherapeutics (NASDAQ:IOVA) with a $5 price target.
The research firm remains confident about the company’s outlook, impressed by the real-world presentation at ASCO that broadened the commercial and clinical case of candidate drug Amtagvi. The presentations reiterated the drug’s efficacy, safety, and workflow data in the treatment of adults with advanced, unresectable, or metastatic melanoma.
According to Citizens, the presentations affirmed the need for patients to be referred to an adoptive T-cell therapy center before the disease burden becomes severe. Iovance has already started advancing in non-small cell lung cancer, sarcoma, and first-line melanoma.
Chief Executive Officer Frederick Vogt has already reiterated plans to accelerate the adoption and commercial expansion of Amtagvi amid record-high market demand. The company is also positioned for long-term revenue growth, as it has advanced multiple ongoing and new clinical trials.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a commercial-stage biopharmaceutical company pioneering tumor-infiltrating lymphocyte (TIL) therapies to treat cancer. By harvesting and multiplying a patient’s own immune cells, they create personalized immunotherapies designed to recognize and destroy solid tumors.
1. Atai Beckley N.V. (NASDAQ:ATAI)
Share Price: $4.81
Stock Upside Potential: 209.77%
Year to Date Gain: 24.55%
Number of Hedge Fund Holders: 35
Atai Beckley N.V. (NASDAQ:ATAI) is one of the top penny stocks to buy in investors’ stock portfolio. On May 12, ATAI Beckley (NASDAQ:ATAI) delivered solid first-quarter results and a business update as it continues to develop its pipeline.
The company remains on track to proceed with the Phase 3 Pivotal program for BPL-003, a proprietary intranasal formulation of the short-acting psychedelic. The company is also anticipating topline Phase 2 results for VLS-01, an investigational transmucosal (buccal) film containing N,N-Dimethyltryptamine (DMT), in the fourth quarter. It has also posted positive Phase 2a data for EMP-01, its oral medication for the treatment of social anxiety disorder.
According to chief executive officer Srinivas Rao, the $209.9 million in cash as of the end of the first quarter will provide a runway to advance the various clinical programs. Net loss in the first quarter widened to $29.8 million from $26.4 million in the same quarter last year. Strong capital position, pipeline breadth, and clinical catalysts position ATAI Beckley to build sustained clinical and shareholder value.
Atai Beckley N.V. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company. They specialize in developing psychedelic-based therapies for treatment-resistant depression (TRD) and other mental health disorders.
While we acknowledge the potential of ATAI to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ATAI and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: Top 10 Small Cap Stocks With Huge Growth Potential and Renaissance Technologies Returns, AUM, CEO and Top 10 Semiconductor Stock Picks.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
